AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
(marketscreener.com) THOUSAND OAKS, Calif., April 26, 2024 /PRNewswire/ -- Amgen today announced the imminent submission of a Marketing Authorization Application to the European Medicines Agency for teprotumumab, a fully human monoclonal antibody and target…
THOUSAND OAKS, Calif., April 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)… [+16640 chars]
